2020 is the year of many things: global conflict, devastating fires, the COVID-19 pandemic, and now civil unrest in response to racism and police brutality in the United States.
It’s been a tough year for everyone, but it has also brought about renewed conversations on societal progress. How can we improve, where do we go from here, and what changes can we start to make?
Strangely to some, one of those changes is coming in the normalization of psychedelics to treat medical conditions. What was once a stigmatized and prohibited class of substances is quickly having a second wind as a treatment for depression, PTSD, and substance-abuse disorders amongst a handful of many other potential therapeutic needs.
We’re also now starting to deal with a wave of new (and previously undiagnosed) cases of depression and anxiety on the back of the COVID-19 pandemic. One week into June, we’re quickly approaching a point where many people have been at home with limited social interaction (or physical activity) for months on end.
As if on queue, the market for psychedelics companies has started to open up in a big way. More and more companies directly and indirectly invested in psychedelics are coming to public markets, and others are starting to make their moves into psychedelics widely known. 2020 is the year of many things, and it’s looking like
psychedelics is one of them.
Back in May, we highlighted
the impressive rise of a few of the companies involved in the psychedelics market. Those included the recently-public psychedelics companies
Champignon Brands Inc. (
CSE:SHRM) and
Mind Medicine Inc. (
NEO:MMED), as well as indirect investments like those of
Yield Growth Corp. (
CSE:BOSS) and
Revive Therapeutics Ltd. (
CSE:RVV).
Fast-forward a few weeks and we’ve seen even more companies enter the fray. On May 20, fully-integrated psychedelics company
Numinus Wellness Inc. (
TSX-V:NUMI) went public, with business arms in clinic and therapy operation, research and development, and direct selling and distribution of psychedelics. On May 28, Ontario-based
Red Light Holland Corp. (
CSE:TRIP) also began listing with a plan to produce and sale psilocybin in the legal Netherlands market for the time being.
We’re also seeing an increasing wave of acquisitions and pivots into psychedelics from companies previously invested in healthcare, cannabis, and even technology. German medical cannabis distributor
Pharmadrug Inc. (
CSE:BUZZ) acquired
Dutch psychedelics retailer Super Smart, California cannabis company
Hollister Biosciences Inc. (
CSE:HOLL) closed their
acquisition of mushroom-based health product developer AlphaMind Brands Inc., and eCommerce CBD provider
Mota Ventures Corp. (
CSE:MOTA)
acquired pharmaceutical psilocybin manufacturer Verrian Ontario Ltd.
And that’s not including the previous moves of companies like
New Wave Holdings Corp. (
CSE:SPOR) in psychedelics and esports,
Empower Clinics Inc. (
CSE:CBDT) in creating its own psilocybin and psychedelics division, and NewLeaf Brands Inc. recently adding a focus on psychedelics and rebranding as
Mydecine Innovations Group Inc. (
CSE:MYCO).
No matter where you look, people and companies are getting invested in psychedelics. Though this has been a somewhat comprehensive list, there are too many to include and more are continuing to pile in. With more excitement about psychedelics and their importance on one hand, and more viable investing options entering the markets on the other, the future for these alternative medicines seems bright.
New to investing in Healthcare? Check out Stockhouse tips on How to Invest in Healthcare Stocks and some of our Top Healthcare Stocks.
For more of the latest info on Cannabis, check out the Healthcare Trending News hub on Stockhouse.
FULL DISCLOSURE: Yield Growth Corp. is a client of Stockhouse Publishing